EVP R&D, Chief Medical Officer
Wed, Oct 15, 2025
Oct 15
exercised or converted securities in ALKS
5,000 shares @ $19.34
Increased holdings by +6.40%
Net across this filing: -5.10% (-4,000 shares)
Option Exercise
Sale tied to a same-time option exercise